CN114946836A - 一种微组织无血清冻存液及其应用 - Google Patents
一种微组织无血清冻存液及其应用 Download PDFInfo
- Publication number
- CN114946836A CN114946836A CN202210574174.3A CN202210574174A CN114946836A CN 114946836 A CN114946836 A CN 114946836A CN 202210574174 A CN202210574174 A CN 202210574174A CN 114946836 A CN114946836 A CN 114946836A
- Authority
- CN
- China
- Prior art keywords
- serum
- free
- microtissue
- cryopreservation
- freezing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012595 freezing medium Substances 0.000 title claims description 17
- 239000011550 stock solution Substances 0.000 claims abstract description 63
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims abstract description 45
- 239000003112 inhibitor Substances 0.000 claims abstract description 18
- 229940088872 Apoptosis inhibitor Drugs 0.000 claims abstract description 17
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims abstract description 17
- 239000000158 apoptosis inhibitor Substances 0.000 claims abstract description 17
- 239000002577 cryoprotective agent Substances 0.000 claims abstract description 17
- 235000000346 sugar Nutrition 0.000 claims abstract description 16
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 14
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 14
- 229920002521 macromolecule Polymers 0.000 claims abstract description 10
- 238000005138 cryopreservation Methods 0.000 claims description 93
- 238000007710 freezing Methods 0.000 claims description 47
- 230000008014 freezing Effects 0.000 claims description 47
- 239000007788 liquid Substances 0.000 claims description 27
- 239000007853 buffer solution Substances 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 25
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 20
- 238000001816 cooling Methods 0.000 claims description 16
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 claims description 13
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 claims description 13
- 229920001612 Hydroxyethyl starch Polymers 0.000 claims description 13
- 235000006708 antioxidants Nutrition 0.000 claims description 13
- 229940050526 hydroxyethylstarch Drugs 0.000 claims description 13
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 12
- 239000002609 medium Substances 0.000 claims description 11
- 108010024636 Glutathione Proteins 0.000 claims description 10
- 229960003180 glutathione Drugs 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 10
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 9
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 9
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 9
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 9
- 229920002674 hyaluronan Polymers 0.000 claims description 9
- 229960003160 hyaluronic acid Drugs 0.000 claims description 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 8
- 229920002971 Heparan sulfate Polymers 0.000 claims description 8
- 150000008163 sugars Chemical class 0.000 claims description 7
- 239000007640 basal medium Substances 0.000 claims description 6
- 239000002244 precipitate Substances 0.000 claims description 6
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 5
- 229930006000 Sucrose Natural products 0.000 claims description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 5
- 229960004308 acetylcysteine Drugs 0.000 claims description 5
- 108010059480 Chondroitin Sulfate Proteoglycans Proteins 0.000 claims description 4
- 102000005598 Chondroitin Sulfate Proteoglycans Human genes 0.000 claims description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 4
- 239000005715 Fructose Substances 0.000 claims description 4
- 229930091371 Fructose Natural products 0.000 claims description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 4
- 229930003268 Vitamin C Natural products 0.000 claims description 4
- 229930003427 Vitamin E Natural products 0.000 claims description 4
- UVCJGUGAGLDPAA-UHFFFAOYSA-N ensulizole Chemical compound N1C2=CC(S(=O)(=O)O)=CC=C2N=C1C1=CC=CC=C1 UVCJGUGAGLDPAA-UHFFFAOYSA-N 0.000 claims description 4
- 229960000655 ensulizole Drugs 0.000 claims description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 4
- 239000004017 serum-free culture medium Substances 0.000 claims description 4
- 235000019154 vitamin C Nutrition 0.000 claims description 4
- 239000011718 vitamin C Substances 0.000 claims description 4
- 235000019165 vitamin E Nutrition 0.000 claims description 4
- 229940046009 vitamin E Drugs 0.000 claims description 4
- 239000011709 vitamin E Substances 0.000 claims description 4
- UOIYRSJJBGZRRI-BYPYZUCNSA-N (2R)-2-(acetyloxyamino)-3-sulfanylpropanoic acid Chemical compound C(C)(=O)ON[C@@H](CS)C(=O)O UOIYRSJJBGZRRI-BYPYZUCNSA-N 0.000 claims description 3
- YDDUMTOHNYZQPO-UHFFFAOYSA-N 1,3-bis{[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy}-4,5-dihydroxycyclohexanecarboxylic acid Natural products OC1C(O)CC(C(O)=O)(OC(=O)C=CC=2C=C(O)C(O)=CC=2)CC1OC(=O)C=CC1=CC=C(O)C(O)=C1 YDDUMTOHNYZQPO-UHFFFAOYSA-N 0.000 claims description 3
- IVVNZDGDKPTYHK-JTQLQIEISA-N 1-cyano-2-[(2s)-3,3-dimethylbutan-2-yl]-3-pyridin-4-ylguanidine Chemical compound CC(C)(C)[C@H](C)N=C(NC#N)NC1=CC=NC=C1 IVVNZDGDKPTYHK-JTQLQIEISA-N 0.000 claims description 3
- YSUBLPUJDOWYDP-UHFFFAOYSA-N 2-[4-[(2,5-difluorophenyl)methoxy]phenoxy]-5-ethoxyaniline Chemical compound NC1=CC(OCC)=CC=C1OC(C=C1)=CC=C1OCC1=CC(F)=CC=C1F YSUBLPUJDOWYDP-UHFFFAOYSA-N 0.000 claims description 3
- SITQVDJAXQSXSA-CEZRHVESSA-N Cynarin Natural products O[C@@H]1C[C@@](C[C@H](O)[C@H]1OC(=O)C=Cc2ccc(O)c(O)c2)(OC(=O)C=Cc3cccc(O)c3O)C(=O)O SITQVDJAXQSXSA-CEZRHVESSA-N 0.000 claims description 3
- YDDUMTOHNYZQPO-RVXRWRFUSA-N Cynarine Chemical compound O([C@@H]1C[C@@](C[C@H]([C@@H]1O)O)(OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 YDDUMTOHNYZQPO-RVXRWRFUSA-N 0.000 claims description 3
- 229940126560 MAPK inhibitor Drugs 0.000 claims description 3
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 claims description 3
- 108010067787 Proteoglycans Proteins 0.000 claims description 3
- 102000016611 Proteoglycans Human genes 0.000 claims description 3
- 108091005735 TGF-beta receptors Proteins 0.000 claims description 3
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 claims description 3
- 229950009125 cynarine Drugs 0.000 claims description 3
- YDDUMTOHNYZQPO-BKUKFAEQSA-N cynarine Natural products O[C@H]1C[C@@](C[C@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)(OC(=O)C=Cc3ccc(O)c(O)c3)C(=O)O YDDUMTOHNYZQPO-BKUKFAEQSA-N 0.000 claims description 3
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 claims description 3
- 229960003987 melatonin Drugs 0.000 claims description 3
- 229960002310 pinacidil Drugs 0.000 claims description 3
- 239000013049 sediment Substances 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 239000000047 product Substances 0.000 claims description 2
- 239000003973 paint Substances 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 abstract description 25
- 238000011084 recovery Methods 0.000 abstract description 18
- 210000002966 serum Anatomy 0.000 abstract description 7
- 230000008901 benefit Effects 0.000 abstract description 2
- 210000002220 organoid Anatomy 0.000 description 103
- 210000004027 cell Anatomy 0.000 description 101
- 239000000243 solution Substances 0.000 description 42
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 28
- 239000000725 suspension Substances 0.000 description 26
- 239000001963 growth medium Substances 0.000 description 21
- 230000000052 comparative effect Effects 0.000 description 18
- 230000029087 digestion Effects 0.000 description 18
- 238000012258 culturing Methods 0.000 description 17
- 239000006228 supernatant Substances 0.000 description 17
- 230000000694 effects Effects 0.000 description 15
- 229910052757 nitrogen Inorganic materials 0.000 description 14
- 230000004083 survival effect Effects 0.000 description 8
- 239000008188 pellet Substances 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 238000001514 detection method Methods 0.000 description 6
- 206010006187 Breast cancer Diseases 0.000 description 5
- 208000026310 Breast neoplasm Diseases 0.000 description 5
- 206010005003 Bladder cancer Diseases 0.000 description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 239000003223 protective agent Substances 0.000 description 4
- 210000000813 small intestine Anatomy 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 229960004793 sucrose Drugs 0.000 description 4
- 201000005112 urinary bladder cancer Diseases 0.000 description 4
- 102100032912 CD44 antigen Human genes 0.000 description 3
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 3
- 101000610551 Homo sapiens Prominin-1 Proteins 0.000 description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 description 3
- 102100040120 Prominin-1 Human genes 0.000 description 3
- 206010038389 Renal cancer Diseases 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 230000025164 anoikis Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 238000012054 celltiter-glo Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 201000010982 kidney cancer Diseases 0.000 description 3
- 108010082117 matrigel Proteins 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000010257 thawing Methods 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 102000015735 Beta-catenin Human genes 0.000 description 2
- 108060000903 Beta-catenin Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 101000687905 Homo sapiens Transcription factor SOX-2 Proteins 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 description 2
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 description 2
- 108700005075 Regulator Genes Proteins 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000012466 permeate Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000004017 vitrification Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- FLEHQRTTWKDNGI-XTJILODYSA-N (1s,3r)-5-[(2e)-2-[(7ar)-1-[(2s)-5-(cyclopropylamino)pentan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-2-methylidenecyclohexane-1,3-diol Chemical compound C([C@H](C)C1[C@]2(CCCC(/C2CC1)=C\C=C1C[C@@H](O)C(=C)[C@@H](O)C1)C)CCNC1CC1 FLEHQRTTWKDNGI-XTJILODYSA-N 0.000 description 1
- 108090000672 Annexin A5 Proteins 0.000 description 1
- 102000004121 Annexin A5 Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102100030613 Carboxypeptidase A1 Human genes 0.000 description 1
- 102100030614 Carboxypeptidase A2 Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010040476 FITC-annexin A5 Proteins 0.000 description 1
- 101000772551 Homo sapiens Carboxypeptidase A1 Proteins 0.000 description 1
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 description 1
- 108091006675 Monovalent cation:proton antiporter-2 Proteins 0.000 description 1
- 238000001190 Q-PCR Methods 0.000 description 1
- 102100038081 Signal transducer CD24 Human genes 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 102000013814 Wnt Human genes 0.000 description 1
- 108050003627 Wnt Proteins 0.000 description 1
- 230000004156 Wnt signaling pathway Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000005775 apoptotic pathway Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 238000011072 cell harvest Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000002338 cryopreservative effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000012137 double-staining Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000006624 extrinsic pathway Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000009746 freeze damage Effects 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000006623 intrinsic pathway Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004216 mammary stem cell Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000005776 mitochondrial apoptotic pathway Effects 0.000 description 1
- 230000006667 mitochondrial pathway Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003761 preservation solution Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0221—Freeze-process protecting agents, i.e. substances protecting cells from effects of the physical process, e.g. cryoprotectants, osmolarity regulators like oncotic agents
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0226—Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210574174.3A CN114946836A (zh) | 2022-05-25 | 2022-05-25 | 一种微组织无血清冻存液及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210574174.3A CN114946836A (zh) | 2022-05-25 | 2022-05-25 | 一种微组织无血清冻存液及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114946836A true CN114946836A (zh) | 2022-08-30 |
Family
ID=82956607
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210574174.3A Pending CN114946836A (zh) | 2022-05-25 | 2022-05-25 | 一种微组织无血清冻存液及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114946836A (zh) |
Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0525001A (ja) * | 1991-07-08 | 1993-02-02 | L Lyndstrom Richard | 血清不含有医療用溶液および眼組織の品質を高める方法 |
CN101983562A (zh) * | 2010-05-26 | 2011-03-09 | 赛业(广州)生物科技有限公司 | 一种非程序细胞冻存液 |
US20130267008A1 (en) * | 2010-12-31 | 2013-10-10 | Kyungpook National University Hospital | Freezing medium composition for cryopreserving amniotic fluid-derived stem cells and a method for cryopreserving the same |
WO2014112675A1 (ko) * | 2013-01-21 | 2014-07-24 | 경북대학교병원 | 골수유래 줄기세포의 천연 냉동보존제 및 이를 이용한 골수유래 줄기세포의 냉동보존방법 |
CN107114355A (zh) * | 2016-08-01 | 2017-09-01 | 北京世纪劲得生物技术有限公司 | 一种脂肪细胞保护液及其制备方法 |
CN109042625A (zh) * | 2018-08-01 | 2018-12-21 | 广州润虹医药科技股份有限公司 | 一种冻存液及其在脐带间充质干细胞冻存中的应用 |
CN109090100A (zh) * | 2018-08-27 | 2018-12-28 | 深圳市浊安认证生物技术有限公司 | 一种间充质干细胞冻存液及其制备方法与使用方法 |
CN111034713A (zh) * | 2019-12-31 | 2020-04-21 | 广州市拜沃思生物科技有限公司 | 一种冻存大体积脂肪组织的方法 |
CN111418581A (zh) * | 2020-06-10 | 2020-07-17 | 上海伯豪生物技术有限公司 | 用于保持组织样本高细胞活性的保存液及保存方法 |
CN111789104A (zh) * | 2019-04-09 | 2020-10-20 | 北京大学第三医院(北京大学第三临床医学院) | 一种冷冻保存液在干细胞冻存中的应用 |
WO2020264313A1 (en) * | 2019-06-28 | 2020-12-30 | Zymo Research Corporation | Compositions for the stabilization of cell-free nucleic acids and methods thereof |
CN112655700A (zh) * | 2020-12-23 | 2021-04-16 | 上海拜羡生物科技有限公司 | 冻存液在胆囊干细胞中的应用及胆囊干细胞的复苏方法 |
WO2021088119A1 (zh) * | 2019-11-08 | 2021-05-14 | 合肥中科普瑞昇生物医药科技有限公司 | 原代乳腺上皮细胞培养基、培养方法及其应用 |
CN113854280A (zh) * | 2021-09-06 | 2021-12-31 | 创芯国际生物科技(广州)有限公司 | 一种新型的低温保存液及其制备方法和应用 |
-
2022
- 2022-05-25 CN CN202210574174.3A patent/CN114946836A/zh active Pending
Patent Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0525001A (ja) * | 1991-07-08 | 1993-02-02 | L Lyndstrom Richard | 血清不含有医療用溶液および眼組織の品質を高める方法 |
CN101983562A (zh) * | 2010-05-26 | 2011-03-09 | 赛业(广州)生物科技有限公司 | 一种非程序细胞冻存液 |
US20130267008A1 (en) * | 2010-12-31 | 2013-10-10 | Kyungpook National University Hospital | Freezing medium composition for cryopreserving amniotic fluid-derived stem cells and a method for cryopreserving the same |
WO2014112675A1 (ko) * | 2013-01-21 | 2014-07-24 | 경북대학교병원 | 골수유래 줄기세포의 천연 냉동보존제 및 이를 이용한 골수유래 줄기세포의 냉동보존방법 |
CN107114355A (zh) * | 2016-08-01 | 2017-09-01 | 北京世纪劲得生物技术有限公司 | 一种脂肪细胞保护液及其制备方法 |
CN109042625A (zh) * | 2018-08-01 | 2018-12-21 | 广州润虹医药科技股份有限公司 | 一种冻存液及其在脐带间充质干细胞冻存中的应用 |
CN109090100A (zh) * | 2018-08-27 | 2018-12-28 | 深圳市浊安认证生物技术有限公司 | 一种间充质干细胞冻存液及其制备方法与使用方法 |
CN111789104A (zh) * | 2019-04-09 | 2020-10-20 | 北京大学第三医院(北京大学第三临床医学院) | 一种冷冻保存液在干细胞冻存中的应用 |
CN111789106A (zh) * | 2019-04-09 | 2020-10-20 | 北京大学第三医院(北京大学第三临床医学院) | 一种冷冻保存液在器官和组织冻存中的应用 |
WO2020264313A1 (en) * | 2019-06-28 | 2020-12-30 | Zymo Research Corporation | Compositions for the stabilization of cell-free nucleic acids and methods thereof |
WO2021088119A1 (zh) * | 2019-11-08 | 2021-05-14 | 合肥中科普瑞昇生物医药科技有限公司 | 原代乳腺上皮细胞培养基、培养方法及其应用 |
CN111034713A (zh) * | 2019-12-31 | 2020-04-21 | 广州市拜沃思生物科技有限公司 | 一种冻存大体积脂肪组织的方法 |
CN111418581A (zh) * | 2020-06-10 | 2020-07-17 | 上海伯豪生物技术有限公司 | 用于保持组织样本高细胞活性的保存液及保存方法 |
CN112655700A (zh) * | 2020-12-23 | 2021-04-16 | 上海拜羡生物科技有限公司 | 冻存液在胆囊干细胞中的应用及胆囊干细胞的复苏方法 |
CN113854280A (zh) * | 2021-09-06 | 2021-12-31 | 创芯国际生物科技(广州)有限公司 | 一种新型的低温保存液及其制备方法和应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3564356A1 (en) | Solution for cryopreservation of animal cells or animal tissues, cryopreserved product, and cryopreservation method | |
AU2019341538B2 (en) | Method for obtaining an enriched population of functional mesenchymal stem cells, cells obtained thereof and compositions comprising the same | |
TW201534722A (zh) | 含有海藻糖及聚葡糖之哺乳動物細胞移植用溶液 | |
AU2017377309B9 (en) | Mammalian cell cryopreservation liquid | |
CN109511651A (zh) | 一种人脐带间充质干细胞无血清冻存液的制备方法 | |
CN107810948A (zh) | 一种人脐带间充质干细胞的无血清冻存液 | |
CN114557337B (zh) | 脐带间充质干细胞无蛋白非程序冻存液及其制备方法 | |
CN106665559A (zh) | 一种免疫细胞冻存液及其应用 | |
CN114181903A (zh) | 结直肠癌类器官培养基及无支架3d培养方法 | |
CN113424820A (zh) | 一种无血清、无蛋白和无dmso的细胞冻存液及其应用 | |
CN113854280B (zh) | 一种低温保存液及其制备方法和应用 | |
Kuleshova et al. | Vitrification of encapsulated hepatocytes with reduced cooling/warming rates | |
KR20210045443A (ko) | 아카보즈 또는 스타키오스를 포함하는 포유동물 세포 보존용 액 | |
CN113973805A (zh) | 细胞冻存试剂盒及其使用方法 | |
CN114073249A (zh) | 一种人t淋巴细胞的慢速冻存方法 | |
CN109362709A (zh) | 一种胎盘组织保存液及其制备方法 | |
Heine-Dobbernack et al. | Cryopreservation of dedifferentiated cell cultures | |
CN114946836A (zh) | 一种微组织无血清冻存液及其应用 | |
CN107711823A (zh) | 一种常温保存的细胞冻存液及其应用 | |
KR20180109600A (ko) | 동결보존효과가 개선된 줄기세포 동결보존용 조성물 및 이를 이용한 방법 | |
EP3035798B1 (en) | Boron added cell cryopreservation medium | |
Fang et al. | Cryopreservation of embryonic cerebral tissue of rat | |
CN112425603B (zh) | 一种脂肪干细胞运输保存液 | |
CN108124853A (zh) | 一种间充质干细胞的保存方法 | |
CN113367123B (zh) | 一种细胞冻存方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Country or region after: China Address after: 610043 No. 702, unit 2, building 1, No. 818, Xingshi Road, Wuhou District, Chengdu, Sichuan Applicant after: Chengdu nuoyeide medical laboratory Co.,Ltd. Applicant after: Shenzhen Jingke Biotechnology Co.,Ltd. Address before: 610043 No. 702, unit 2, building 1, No. 818, Xingshi Road, Wuhou District, Chengdu, Sichuan Applicant before: Chengdu nuoyeide medical laboratory Co.,Ltd. Country or region before: China Applicant before: GUAGNZHOU JINGKE BIOTECH CO.,LTD. |